Hyunho LEE

CTO VSPharmTech

Seminars

Thursday 29th January 2026
Modulating DDR in GBM to Enable Radiosensitizer-Driven Combination Strategies
10:15 am

• See how VSPharmTech is developing VS-101 to enable radiosensitizer-driven strategies in glioblastoma

• Clarifying synthetic lethality and combination strategies in GBM

• Exploring regulatory and orphan drug designation progress

Hyun-Ho Lee, Chief Technology Officer & Head of R&D at VSPharmTech, speaker at DDR Inhibitors